Mimotopes to produce peptides for Invitrogen
Thursday, 06 October, 2005
Mimotopes, a wholly owned subsidiary of PharmAust (ASX:PAA), is to supply California-based life science technology group Invitrogen Corporation (NASDAQ:IVGN) with custom pre-clinical peptides for Invitrogen's customers worldwide.
The preferred outsourcing agreement is on a 12-month rolling term. An initial standing order of custom peptides has been placed valued at between AUD$130,000 and AUD$200,000 per month. Mimotopes expects to generate initial revenues of over AUD$1.5 million per annum from the contract.
With a market capitalisation of US$4 billion, Invitrogen provides technologies for disease research, drug discovery and commercial bioproduction to research institutions, pharmaceuticals and biotechnology companies.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
